KalVista Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference
KalVista Pharmaceuticals (Nasdaq: KALV) will present at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026, at 10:15 a.m. EST in a fireside chat.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
A live audio webcast of the presentation will be accessible on the Investors section of the Company’s website at www.ir.kalvista.com/event-calendar. An archived replay will be available approximately two hours after the completion of the events.
About KalVista Pharmaceuticals, Inc.
KalVista is a global pharmaceutical company dedicated to delivering life-changing oral therapies for individuals affected by rare diseases with significant unmet needs. The KalVista team discovered and developed EKTERLY®—the first and only oral on-demand treatment for hereditary angioedema (HAE)—and continues to work closely with the global HAE community to improve treatment and care for this disease around the world. For more information about KalVista, please visit www.kalvista.com and follow us on LinkedIn, X, Facebook and Instagram.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260408256306/en/
Investors:
Ryan Baker
Head, Investor Relations
(617) 771-5001
ryan.baker@kalvista.com
Media:
Molly Cameron
Sr. Director, Corporate Communications
(857) 356-0164
molly.cameron@kalvista.com
Source: KalVista Pharmaceuticals, Inc.